

Special Issue

Vaccines against Influenza Virus

Message from the Guest Editor

Influenza can cause viral pneumonia, especially in the elderly, the chronically ill and the very young, which can lead to breathing difficulties and serious complications. Influenza vaccination is the most effective measure to prevent influenza. However, the understanding of influenza vaccine is far from enough. We are pleased to invite you to contribute this special issue on influenza vaccine. The issue aims to discuss the vaccine and related issues, including the epidemic characteristics of influenza under the COVID-19 pandemic, the impact of specific prevention strategies on the epidemic trend, the cross-protection of influenza vaccine, influenza virus variation and control strategies, and the development of new influenza vaccine, etc. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but not limited to) the following: Epidemiology, clinical trial, Meta-analysis, real world evaluation on influenza vaccine. We look forward to receiving your contributions. Dr. Fuqiang Cui

Guest Editor

Prof. Dr. Kevin Coombs

Department of Medical Microbiology, Rady Faculty of Health Sciences,
University of Manitoba, Winnipeg, MB R3E 0J9, Canada

Deadline for manuscript submissions

closed (30 September 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/114052

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).